Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Sionna Therapeutics Announces $182 Million Series C

2024-03-06
BOSTON, MA, Sionna Therapeutics, a clinical-stage life sciences company, announced the closing of a $182 million Series C financing to support the clinical development.
Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), announced the closing of a $182 million Series C financing to support the clinical development of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein by stabilizing the first nucleotide-binding domain (NBD1).
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors